---
title: "Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/212040667.md"
description: "Johnson & Johnson announced that the FDA approved Rybrevant plus Lazcluze, marking the first chemotherapy-free option for treating adults with non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. This approval follows positive Phase 3 MARIPOSA study results, demonstrating a 30% reduction in disease progression or death compared to the existing treatment, osimertinib. Rybrevant is also approved for other forms of NSCLC with different mutations. The approval signifies a significant advancement in lung cancer treatment options."
datetime: "2024-08-20T11:57:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/212040667.md)
  - [en](https://longbridge.com/en/news/212040667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/212040667.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/212040667.md) | [繁體中文](https://longbridge.com/zh-HK/news/212040667.md)


# Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod

Johnson & Johnson (JNJ) Tuesday said the Food and Drug Administration or FDA has approved Rybrevant plus Lazcluze, the first and only chemotherapy-free regimen for the first-line treatment of adults with non-small cell lung cancer (NSCLC) having epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.

The FDA approval is based on positive results from the Phase 3 MARIPOSA study, which showed Rybrevant plus Lazcluze reduced the risk of disease progression or death by 30 percent compared to AstraZeneca's osimertinib in the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Osimertinib with chemotherapy was already approved by the FDA for the treatment of EGFR-mutated non-small cell lung cancer.

Rybrevant in combination with chemotherapy is already approved for the first-line treatment of patients with NSCLC having EGFR exon 20 insertion mutations.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [Johnson & Johnson (JNJ.US)](https://longbridge.com/en/quote/JNJ.US.md)
- [SHANGHAI FOREIGN SERVICE HOLDING (600662.CN)](https://longbridge.com/en/quote/600662.CN.md)

## Related News & Research

- [Daratumumab becomes first oncology injectable approved for patient administration](https://longbridge.com/en/news/280990101.md)
- [Guan Chao's Loss Balloons in 2025](https://longbridge.com/en/news/281314987.md)
- [CoreCap Advisors LLC Boosts Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/280975756.md)
- [Warren Buffett Bet Big On Oil In Q4: Here's How Much Berkshire Hathaway Is Up On Chevron Stock In 2026](https://longbridge.com/en/news/281213097.md)
- [Warren Buffett Says He'd Buy 'A Whole Lot' Of Apple If It Gets Cheaper— And He's Not Losing Sleep Over Cashing Out $100 Billion Stake](https://longbridge.com/en/news/281202027.md)